What's at stake: Philip Oliver, co-founder of Nelson-based biotech company Kimer Med, has put part of his stake up for sale on the Catalist exchange and is no longer involved on a daily basis in the company.
Background: US-based Oliver and co-founder Rick Kiessig started the company in 2020 during the Covid pandemic to develop a platform of broad-spectrum antiviral drugs. It closed a $14m Series A round last October.
Key players: Rick Kiessig, Philip Oliver, Catalist, John Laloli, Kimer Med.
Kimer Med co-founder Philip Oliver has put part of his 27% stake in the Nelson-based biotech company up for sale on the Catalist exchange.
He and CEO Rick Kiessig co-founded the company in 2020 during the Covid pandemic when the world was seeking effective antiviral medicine.
Sign up to get the latest stories and insights delivered to your inbox – free, every day.
Key points
What's at stake: Philip Oliver, co-founder of Nelson-based biotech company Kimer Med, has put part of his stake up for sale on the Catalist exchange and is no longer involved on a daily basis in the company.
Background: US-based Oliver and co-founder Rick Kiessig started the company in 2020 during the Covid pandemic to develop a platform of broad-spectrum antiviral drugs. It closed a $14m Series A round last October.
Key players: Rick Kiessig, Philip Oliver, Catalist, John Laloli, Kimer Med.
